Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO
Executive Summary
Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range
You may also be interested in...
Is Ironwood The IPO Medicine To Get Things Moving?
Ironwood Pharmaceuticals' $188 million IPO was like the proverbial elephant among the blind men. How you perceived it depended upon where you touched it
Venture Investment Plummets In 2009 As VCs Retrench
Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.
Venture Investment Plummets In 2009 As VCs Retrench
Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.